Quote Cart
Plant Types: Pharmaceutical
Subtypes: Solid Dose, Bottle Filling Line, Capsule Dose
Capacity: 2-3 Billion Doses/Year
Facility Details
90,000 sq. ft. OSD Manufacturing Site
Designed for tablets, capsules, powders, and sachets, this Oral Solid Dose (OSD) manufacturing facility is immediately available for redeployment/operation. The facility was previously operated under US FDA regulations until its idling in 2025.
From blending and tableting to fluid bed drying, pan coating, and packaging, this facility has it all. With GMP-compliant workflows, serialized packaging lines, a DEA vault, and robust utilities, the system is built for high-output, regulated production with minimal ramp-up.
Suitable Uses
Manufacturing Assets
Dispensing / Weighing
Milling / Sieving
Blending / Mixing
Precision Dispensing & Weighing Equipment
Granulation
Drying (for wet granulation)
Milling & Particle Size Control Equipment
Compression / Tableting
Tablet Coating
Encapsulation
Final Dose Formation Equipment
In-Process Testing (IPT)
Bottling / Blister Packaging
Final Quality Control (QC) Testing
Storage / Warehousing
Utilities & Site Infrastructure
Control & Support Systems
Special Features
Plant Layout Overview
Main Floor: 65,860 Sq. Ft.
Second Floor: 26,794 Sq. Ft.
Total: 92,654 sq. ft.
Why This Plant?
Plant Types: Pharmaceutical
Subtypes: API
UNUSED state-of-the-art highly flexible small molecule manufacturing facility constructed in 2011The facility is capable of producing around 400kg of API per year, allowing for the production of batches from lead to candidate through to Phase III and commercial launch quantities. This is the potential capacity, in a configuration of people working in 2x7h on 5 days, but this tool could be operated on a 24x7 basis if needed, in which case higher levels of output could be achieved. Production capacity remains dependent on the type and number of synthesis steps.
PILOT PLANT
Plant Types: Chemical and Specialty Chemical, Pharmaceutical, Fertilizer and Agrochemical
Subtypes: API
Capacity: ~1,200m3 Total Reactor Capacity
190 Acre API Manufacturing Plant Complex Grimsby, England, UK
This world-class, fully integrated API manufacturing site, formerly operated by Novartis, includes over 1,200m3 of total reactor vessel capacity across three distinct production buildings, available for sale or lease as a whole site or individual buildings for operation in-place. The facility could be utilized for pharmaceutical and animal health API manufacturing or repurposed for specialty/fine chemical manufacturing, flavors and fragrances, or agrochemicals.
VIDEO: https://www.youtube.com/watch?v=AUWUHnAyWos&list=PLRlhdb05DXKR4eyHsLOkB6NzTyh2R4YCE
The site is located adjacent to the river Humber and between the Immingham and Grimsby port facilities, less than 5 minutes from downtown Grimsby, 25 minutes from Humberside Airport, 2.5 hours from Manchester Airport, 3.5 hours from London Heathrow.
Inside the fenceline is approximately 100 acres, with significant development land and infrastructure available inside the fence. There is an additional approximately 90 acres of agricultural land outside the fenceline.
Facility has the capabilities to perform various chemical synthesis, including hydrogenation, Grignard/Friedel-Crafts Reactions, Azide, and Tin Chemistries.
Building 110: Multi-product, Multi-purpose facility (ca. 1993)
Building 120: Mixed High Volume, Multi-Purpose Facility (ca. 1994/2007)
Building 150: High Volume, Multi-Product Facility (ca. 2004/2007)
Each building has its own dedicated solvent storage and recovery, in-process lab spaces, workshops, and offices.
Site Utilities:
The production buildings are supported by the following non-production infrastructure:
Warehousing:
The facility was not used in production of of plant/animal extracts, fermentation, penicilin, beta-lactams, steroids, hormonals, or cytoxic compounds.